Chantix_(Critical_Review)

Paddock, C. (2008, January 21). Chantix Label Updated To Warn Of Suicide Risk. Retrieved September 12, 2010, from http://www.medicalnewstoday.com/articles/94593.php Who-Catharine Paddock has a Bachelor of Science in Chemistry with Physics and a PhD in Business Administration from the Manchester Business School at the University of Manchester, UK. She has also trained as a counselor, specializing in cognitive behavioral and brief therapy. She also spent five years working with employee counseling organizations, running workshops, trauma debriefs and seeing clients in one to one therapy. Her credentials are very specific for this article. What-The recent drug Chantix® is the first non-nicotine based smoking cessation drug to come out within the past 10 years, but the psychological side effects may not be worth it. This argument is very logical, though smoking is one of the leading causes of avoidable premature deaths, depression and thoughts of suicide may be slightly less desirable than an early death. This seems very reasonable, and the only evidence against it is stated in the article, where many of the drug trials done have shown that psychological effects were caused by patients that already exhibited some sort of psychological illness. How-Trials using the drug vs. a placebo were mentioned, as well as the results of other patients that have already used Chantix® and information on how it affected them. Since that majority of the supporting evidence is independent of the company who actually sells the drug, it is credible and is the exact kind of evidence I would think was needed to test the argument. When-This article was posted 21 Jan 2008 - 3:00 PDT. It is current and should stand the test of time due to its credible resources and logical arguments, but science is always growing and improving. Where-Medical News Today has well-regarded sources such as JAMA, BMJ, Lancet, BMA, plus articles written by their own team of independent researchers, their main goal is to keep anyone interested, updated on health related issues. Summarize-This article is fully justifiable based on the evidence of trails done with the drug Chantix® and with the many cited sources, and quotes from other doctors who worked with the study, or who has worked with the drug prior to this article. Smoking can greatly reduce the longevity of an individual’s lifespan, and this new drug which works to decrease the effects nicotine has on the release of dopamine in the brain and blocks nicotine receptors, seems to be a valuable tool in fighting a smoking habit, but of course the neurological repercussions should be first considered. This article does an excellent job of evaluating the drug, and informing an individual of the potential and risks of this recent smoking cessation drug.